FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma

Evidence for efficacy is based on the results from BGB-3111-206 and BGB-3111-AU-003 studies
19 Nov 2019
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 14 November 2019, the US Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Efficacy was evaluated in BGB-3111-206 (NCT03206970), a phase II open-label, multicentre, single-arm trial of 86 patients with MCL who received at least one prior therapy. Zanubrutinib was given orally at 160 mg twice daily until disease progression or unacceptable toxicity. Efficacy was also assessed in BGB-3111-AU-003 (NCT 02343120), a phase I/II, open-label, dose-escalation, global, multicentre, single-arm trial of B‑cell malignancies, including 32 previously treated MCL patients treated with zanubrutinib administered orally at 160 mg twice daily or 320 mg once daily.

The primary efficacy outcome measure in both trials was overall response rate (ORR), as assessed by an independent review committee. In trial BGB-3111-206, FDG-PET scans were required and the ORR was 84% (95% CI: 74, 91), with a complete response rate of 59% (95% CI 48, 70) and a median response duration of 19.5 months (95% CI: 16.6, not estimable). In trial BGB-3111-AU-003, FDG-PET scans were not required and the ORR was 84% (95% CI: 67, 95), with a complete response rate of 22% (95% CI: 9, 40) and a median response duration of 18.5 months (95% CI: 12.6, not estimable).

The most common adverse reactions (≥20%) included decreased neutrophil count, decreased platelet count, upper respiratory tract infection, decreased white blood cell count, decreased haemoglobin, rash, bruising, diarrhoea, and cough. The most common serious adverse reactions were pneumonia in 11% and haemorrhage in 5% of patients. 

The recommended zanubrutinib dose is 160 mg orally twice daily or 320 mg orally once daily.

Full prescribing information for BRUKINSA is available here.

FDA granted this application priority review and zanubrutinib received orphan product and breakthrough therapy designations for treatment of MCL.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA Oncology Center of Excellence’s Project Facilitate.

Last update: 19 Nov 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings